Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression

Author： Kretz-Rommel Anke Bowdish Katherine S

Publisher： Informa Healthcare

ISSN： 1471-2598

Source： Expert Opinion on Biological Therapy, Vol.8, Iss.1, 2008-01, pp. : 5-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road

By Gill Saar Porter David L

Expert Opinion on Biological Therapy, Vol. 14, Iss. 1, 2014-01 ,pp. : 37-49

Informa Healthcare

Access to resources Recommend Favorite

Immune alterations in malignant melanoma and current immunotherapy concepts

By Shimanovsky Alexei Jethava Ashif Dasanu Constantin A

Expert Opinion on Biological Therapy, Vol. 13, Iss. 10, 2013-10 ,pp. : 1413-1427

Informa Healthcare

Access to resources Recommend Favorite

Immunotherapy for gynaecological malignancies

By Coukos George Conejo-Garcia Jose R Roden Richard BS Wu T-C

Expert Opinion on Biological Therapy, Vol. 5, Iss. 9, 2005-09 ,pp. : 1193-1210

Informa Healthcare

Access to resources Recommend Favorite

Anti-CD3 scFv-B7.1 fusion protein expressed on the surface of HeLa cells provokes potent T-lymphocyte activation and cytotoxicity

By Yang Zhang-Min Li En-Min Lai Bao-Chang Wang Yi-Li Si Lu-Sheng

Biochemistry and Cell Biology, Vol. 85, Iss. 2, 2007-04 ,pp. : 196-202

NRC Research Press

Access to resources Recommend Favorite

Ofatumumab, a human anti-CD20 monoclonal antibody

By Österborg Anders

Expert Opinion on Biological Therapy, Vol. 10, Iss. 3, 2010-03 ,pp. : 439-449

Informa Healthcare

Access to resources Recommend Favorite